Efficacy and safety of combined immunoprophylaxis of ARVI and influenza in children with bronchial asthma
In 128 children with bronchial asthma the triggers of disease exacerbation were studied. As was found, in 75% of cases risk factors for relapses of bronchial asthma were acute respiratory viral infections (OR = 7.5; <i>p </i>< 0.5). Climatic, allergic and other provoking factors acted as triggers considerably more rarely. In 56 children aged 9-17 years, in whom triggers of bronchial asthma relapse were acute respiratory infections, the efficacy and safety of influenza vaccination and ribosomal immunization were studied. Vaccination against influenza in combination with ribosomal immunization was characterized by good tolerance, high immunological and therapeutic and preventive effectiveness, which permitted to reduce the incidence rate of acute respiratory infections, shorten their duration, and to decrease the incidence of relapses of bronchial asthma (p < 0.05). The use of combined immunoprophylaxis of ARVI and influenza in complex therapy of children with bronchial asthma permitted to control the course of disease at a lower stage of basic therapy in 68.4% of cases <i>(p </i>< 0.05).